[Experiences with a new cat coryza-panleukopenia-rabies combined vaccine].
The development of a new combined vaccine against cat flu, panleukopenia and rabies should lead to a simplification of the vaccination calendar in small animal practice. In order to judge the suitability of the new vaccine, its efficacy, local tolerability, and safety were evaluated. All vaccinated cats developed high antibody titres against herpes-, calici-, panleukopenia- and rabies virus that persisted well during the trial of 18 months. In comparison to other vaccines containing a smaller number of antigens the suitability of the vaccine on trial could be shown.
Franke
V
V
Behringwerke AG, Marburg/Lahn.
Danner
K
K
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002139:Caliciviridae / Q000276:immunology*; D002371:Cat Diseases / Q000517:prevention & control; D002415:Cats; D004338:Drug Combinations; D028301:Feline Panleukopenia Virus / Q000276:immunology*; D006564:Herpesviridae / Q000276:immunology*; D011819:Rabies Vaccines / Q000009:adverse effects / Q000276:immunology*; D014611:Vaccination / Q000662:veterinary; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*
D000914:Antibodies, Viral; D004338:Drug Combinations; D011819:Rabies Vaccines; D014765:Viral Vaccines
Erfahrungen mit einem neuen Katzenschnupfen-Panleukopenie-Tollwut-Kombinationsimpfstoff.